Vistagen Therapeutics (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of Vistagen's CNS drug candidates, PH94B, PH10, and AV-101, has a differentiated mechanism of action, a favorable safety profile in all clinical studies to date, and therapeutic potential in multiple CNS markets.
Events & Presentations
Latest Quarterly or Annual Filing
Quarterly report which provides a continuing view of a company's financial position